Henlius Biotech’s HLX04-O Accepted by NMPA for Wet AMD Treatment
Shanghai Henlius Biotech Inc. (HKG: 2696) announced on August 13, 2025, that the marketing authorization...
Henlius Biotech
Henlius’ HLX43 Approved by FDA for Phase 1 Trial in Thymic Carcinoma Treatment
China’s Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the U.S. Food and Drug Administration...
Henlius Biotech’s HLX14 Recommended for EU Approval by EMA’s CHMP
China-based Shanghai Henlius Biotech, Inc. (HKG: 2696) announced on July 28, 2025, that the European...
Shanghai Henlius Biotech Initiates US Patient Dosing in Phase III Trial for HER2-Positive Gastric Cancer
China-based Shanghai Henlius Biotech Inc., (HKG: 2696) announced the first patient dosing in the US...
Shanghai Henlius Biotech Earns GMP Certification for Prolia/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11
China’s Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has received Good Manufacturing Practice...
Fosun Pharma’s Serplulimab Approved for ES-SCLC in the UK and India
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai...
Henlius Biotech Doses First Patient in Japanese Bridging Trial of Serplulimab for ES-SCLC
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced the successful completion of first patient dosing...
Shanghai Henlius Biotech Partners with Shanghai Chest Hospital for Clinical Research and Talent Development
China’s Shanghai Henlius Biotech Inc., (HKG: 2696) this week entered into a strategic collaboration agreement...
Fosun Pharma’s Serplulimab Approved in Singapore and Malaysia for ES-SCLC Treatment
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai...
Henlius Biotech Starts Global Phase II Trial for PD-L1 ADC HLX43
China’s Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing in a global,...
Shanghai Henlius Biotech Doses First Patient in Phase I/III Study of HLX13 for Hepatocellular Carcinoma
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the completion of first patient dosing in a...
Fosun Pharma’s Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary...
Henlius Biotech’s HLX22 Receives Clinical Trial Approval in Germany for HER2-Positive Cancers
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced that it has received clinical trial approval...
Shanghai Henlius and Alvogen Korea Ink Licensing Deal for HanSiZhuang (Serplulimab)
China-based Shanghai Henlius Biotech Inc., (HKG: 2696) has entered into a licensing agreement with South...
Shanghai Henlius Initiates Phase II Study of HLX22 in HER2 Low Breast Cancer
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first patient dosing in a...
Henlius Biotech’s HLX04-O Shows Positive Results in wAMD Phase III Trial
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced positive results from the Phase III...
Henlius and Organon’s HLX11 Biosimilar Clears EMA Validation Hurdle
Shanghai Henlius Biotech, Inc. (HKG: 2696) and Organon (NYSE: OGN) announced that the European Medicines...
Shanghai Henlius Biotech Receives NMPA Approval for HLX79 in Glomerulonephritis Trial
China’s Shanghai Henlius Biotech Inc. (HKG: 2696) has announced receiving approval from the National Medical...
Henlius Biotech Reports 6.1% Revenue Growth with Strong Oncology Product Sales
Shanghai Henlius Biotech Inc. (HKG: 2696) has published its 2024 financial results, recording revenues of...
Fosun’s Henlius Receives FDA Orphan Drug Designation for HER2-Targeting HLX22
On March 19, 2025, Fosun Pharmaceutical (SHA: 600196) announced that its subsidiary, Henlius, has received...